Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with chemotherapy with or without tremelimumab versus chemotherapy in first-line advanced urothelial cancer
jRCT2080224099Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tremelimumab, cisplatin, carboplatin and gemcitabine in transitional cell carcinoma (TCC) (3 arms), sponsored by AstraZeneca. Started Oct 2018; status: completed.
02
Drugs
durvalumabtremelimumabcisplatincarboplatingemcitabine
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2080224099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224099.